CDER Manual of Policies & Procedures | MAPP
CDER's Manual of Policies and Procedures (MAPPs) are federal directives and documentation of internal policies and procedures. MAPPs are required by law and made available to the public to make CDER a more transparent organization. A MAPP may be removed from this FDA.gov page while it is being evaluated and updated. For more information about MAPPs, please contact the CDER MAPP Team: [email protected]
This page contains the current CDER Manual of Policies and Procedures (MAPPs) in Adobe Acrobat Format (PDF).
| MAPP # | Office | Title | Category | Date Posted |
|---|---|---|---|---|
| MAPP 5019.2 | Office of Pharmaceutical Quality | Assessment of the Appropriate Net Container Content for Injectable Drug and Biological Products | Regulatory Review and Scientific Policies | 6/13/2022 |
| MAPP 5223.6 | Office of Generic Drugs | Assessment of the User Interface of a Drug-Device Combination Product Submitted in a Pre-ANDA Communication or an ANDA | Generic Drug Review | 6/7/2022 |
| 5220.3 | Office of Generic Drugs | Communicating Certain Deficiencies Identified During Filing Review of ANDAs | Generic Drug Review | 9/28/2017 |
| 5240.10 | Office of Generic Drugs | Classifying Approved New Drug Products and Drug-device Combination Products as Complex Products for Generic Drug Development Purposes | Generic Drug Review | 04/13/2022 |
| 4151.8 Rev. 1 | Office of Executive Program | Equal Voice: Collaboration and Regulatory and Policy Decision-Making in CDER | Staff Resources & Services | 04/12/2022 |
| 5019.1 Rev.1 | Office of Pharmaceutical Quality | Allowable Excess Volume/Content in Injectable Drug and Biological Products | Regulatory Review and Scientific Policies | 01/29/2022 |
| 6050.2 | Office of Management | Effect of Failure to Pay BsUFA Fees | Staff Resources and Services | 12/03/2021 |
| 5021.1 Rev.1 | Office of Pharmaceutical Quality | Naming of Drug Products Containing Salt Drug Substances | Regulatory Review and Scientific Policies | 12/7/2017 |
| 4658.4 | Office of Management | CDER FTE Tracking and Table of Organization Review Process | Staff Resources and Services | 5/30/2017 |
| 4200.5 | Office of the Center Director | Commitment of CDER Central Funds to Support Intercenter Science Projects | Leadership and Mission | 3/7/2016 |
| 5021.2 | Office of Pharmaceutical Quality | Evaluating Color Additives and Flavors Intended for Oral Drug Products Submitted or Referenced in INDs and NDAs | Regulatory Review and Scientific Policies | 6/3/2021 |
| 4657.0 Rev. 1 | Office of Management | CDER’s Time, Attendance, and Leave Recording Policy | Staff Resources and Services | 05/19/2021 |
| 7600.10 | Office of Strategic Programs | CDER Master Data Management | Information Technology | 04/15/2022 |
| 7610.8 | Office of Surveillance and Epidemiology | Electronic and Digital Signatures for Records Management | Drug Safety | 04/03/2018 |
| 7610.3 | Office of Surveillance and Epidemiology | Division IT Coordinator Services | Drug Safety | 2/26/2018 |
| 6720.4 | Office of Surveillance and Epidemiology | Procedures for Sharing Non-public Information on Pending Proposed Proprietary Names | Drug Safety | 9/21/2016 |
| 6030.3 | Office of New Drugs | Emergency Investigational New Drug Application Process During and After Normal Business Hours | New Drug Review | 9/5/2018 |
| 6010.11 | Office of the Center Director | Developing and Issuing Drug Trial Snapshots | Leadership and Mission | 11/20/2018 |
| 5241.3 | Office of Generic Drugs and Office of Pharmaceutical Quality | Good Abbreviated New Drug Application Assessment Practices | Generic Drug Review | 01/03/2018 |
| 5240.3 Rev.5 | Office of Generic Drugs | Prioritization of the Review of Original ANDAs, Amendments, and Supplements | Generic Drug Review | 01/30/2020 |
| 5231.2 | Office of the Commisioner | CDER Barcode Inquiries | Public Outreach | 11/15/2018 |
| 5220.5 Rev.1 | Office of Generic Drugs | Issuance of Information Requests and/or Discipline Review Letters for ANDAs under the Reauthorization of GDUFA | Generic Drug Review | 01/26/2022 |
| 5220.1 | Office of Generic Drugs | Receiving and Processing a Request for Voluntary Withdrawal of an Approved ANDA | Generic Drug Review | 10/4/2017 |
| 5200.14 | Office of Generic Drugs | Filing Review of Abbreviated New Drug Applications | Generic Drug Review | 9/1/2017 |
| 5200.12 | Office of Generic Drugs and Office of Pharmaceutical Quality | Communicating Abbreviated New Drug Application Review Status Updates with Industry | Generic Drug Review and Regulatory Review and Scientific Policies | 11/20/2018 |
| 5200.7 Rev.1 | Office of Generic Drugs | ANDA Amendments and Supplements Reviewed by the Division of Filing Review | Generic Drug Review | 4/17/2020 |
| 5022 | Office of Pharmaceutical Quality | Roles and Responsibilities of FDA Liaisons to Standards Development Organizations | Regulatory Review and Scientific Policies | 5/01/2020 |
| 5016.6 | Office of Pharmaceutical Quality | Change in Hard Gelatin Capsule Supplier | Regulatory Review and Scientific Policies | 11/20/2018 |
| 5014.1 | Office of Pharmaceutical Quality | Understanding CDER's Risk-Based Site Selection Model | Regulatory Review and Scientific Policies | 11/10/2015 |
| 5001.1 | Office of Pharmaceutical Quality | Drug Product Distribution After a Complete Response Action to a Changes Being Effected Supplement | Regulatory Review and Scientific Policies | 10/4/2017 |
| 4670.2 | Office of Management | Administrative Leave Requests Related to Performance and Misconduct | Staff Resources and Services | 11/12/2015 |
| 7610.3 | OFFICE OF STRATEGIC PROGRAMS | CDER Division IT Coordinator Services | Information Technology | 2/26/2018 |
| 4657.13 | Office of Management | Compensatory Time Off for Travel | Staff Resources and Services | 5/7/2019 |
| 4643.6 | Office of Management | CDER Scheduling OF WO51/1300 Conference Room | Staff Resources and Services | 4/19/2017 |
| 4640.2 | Office of Management | Internal Organizational Charts | Staff Resources and Services | 6/30/2016 |
| 4410.1 Rev. 1. | Office of Communications | FDA Pharmacy Student Experiential Program | Public Outreach | 8/28/2019 |
| 4100.2 | Office of Translational Science | CDER Staff Participation in Public Private Partnerships and Consortia | Regulatory Review and Innovation | 9/10/2021 |
| 5017.2 Rev.1 | Office of Pharmaceutical Quality | Establishing Impurity Acceptance Criteria As Part of Specifications for NDAs, ANDAs, and BLAs Based on Clinical Relevance | Regulatory Review and Scientific Policies | 5/20/2020 |
| 5242.1 | Office of Generic Drugs | Transfer of Ownership | Generic Drug Review | 8/26/2020 |
| 6701.4 | Office of Surveillance and Epidemiology | Notifying Applicants of Sentinel Analyses and Results | Drug Review | 8/17/2020 |
| 6702.2 | Office of Surveillance and Epidemiology | Determination of the Need for and Review of a New REMS | Drug Review | 6/18/2020 |
| 5220.2 | Offce of Generic Drugs | Conversion of ANDA Approval to Tentative Approval Because of Court Order | Generic Drug Review | 6/11/2020 |
| 4121.3 | Office of the Center Director | Collaborative Identification, Evaluation, and Resolution of a Newly Identified Safety Signal (NISS) | Leadership and Mission | 4/30/2020 |
| 6702.1 | Office of Surveillance and Epidemiology | Risk Evaluation and Mitigation Strategy (REMS) Assessment | Drug Safety | 12/18/2019 |
| 6701.1 | Office of Surveillance and Epidemiology | Procedures for DMEPA Intra-Center Consult to DMPP on Patient-Oriented Labeling Submitted with Human Factors Validation Study Protocols | Drug Safety | 9/18/2019 |
| 5220.8 | Office of Generic Drugs | Evaluating Requests for and Conducting Product Development and Pre-Submission Pre-ANDA Meetings | Generic Drug Review | 9/19/2019 |
| 4191.1 | Office of New Drugs | Risk Evaluation and Mitigation Strategies Modifications and Revisions | New Drug Review | 6/29/2020 |
| 6004.3 | Office of New Drugs | Safety Labeling Changes Under Section 505(o)(4) of the FD&C Act | New Drug Review | 7/09/2019 |
| 5017.4 | Office of Pharmaceutical Quality | Quality Center for Drug Evaluation and Research Biopharmaceutics Council | Regulatory Review and Scientific Policies | 4/24/2019 |
| 6720.5 | Office of Surveillance and Epidemiology | Procedures for Handling Requests for Nonproprietary Name Suffix Review for Biological Products Newly Licensed Under Section 351of the PHS Act | Drug Safety | 3/7/2019 |
| 6701.3 Rev.1 | Office of Surveillance and Epidemiology | Development of a Single, Shared System (SSS) Risk Evaluation and Mitigation Strategy (REMS) or a Separate REMS with Elements to Assure Safe Use (ETASU): Responsibilities and Procedures | Drug Safety | 10/28/2020 |
| 4000.2 | Office of Regulatory Policy | Developing and Issuing Guidance | Regulatory Policy and Information Disclosure | 10/3/2005 |
| 4000.1 Rev.6 | Office of Management | Developing and Issuing MAPPs for CDER | Staff Resources and Services | 9/10/2021 |
| 4000.3 | Office of Regulatory Policy | Submitting Proposals to the Office of Regulatory Policy (ORP) for Early Analysis of Rulemaking Initiatives | Regulatory Policy and Information Disclosure | 10/23/2001 |
| 4000.4 Rev 1 | Office of Translational Sciences | Clinical Pharmacology and Biopharmaceutics NDA Review Template | Regulatory Review and Innovation | 9/22/2016 |
| 4000.10 Rev.1 | Office of New Drugs | Developing Indication-Specific Guidances | New Drug Review | 11/21/2014 |
| 4151.7 | Office of the Center Director | Joint Safety Meetings Between OND and OSE | Leadership and Mission | 3/26/2009 |
| 4151.3 R4 | Office of the Center Director | Drug Safety Oversight Board (DSB) | Leadership and Mission | 9/13/2016 |
| 4150.1 | Office of Executive Programs | Role and Procedures of the CDER Ombudsman | Executive Secretariat | 10/18/2002 |
| 4140.6 | Office of Regulatory Policy | Editing Procedures | Regulatory Policy and Information Disclosure | 12/11/2002 |
| 4140.5 | Office of Regulatory Policy | Submitting Issues/Documents to the Office of the Chief Counsel (OCC) for Legal Review, Comment, or Clearance | Regulatory Policy and Information Disclosure | 3/22/2002 |
| 4112.2 | Office of Executive Programs | Sharing Nonpublic Information with Federal Government Officials. | Regulatory Policy and Information Disclosure | 7/12/2002 |
| 4151.15 | Office of the Center Director | Collaboration in Managing the CDER Drug Quality Oversight Program | Leadership and Mission | 2/1/2013 |
| 4160.2 | Office of Center Director | Prioritization of Requests for Training and Visits by Foreign Regulatory Agencies and International Regulatory Organizations | Leadership and Mission | 5/31/2000 |
| 4180.4 | Office of New Drugs | NDAs/BLAs: Using the 21st Century Review Process Desk Reference Guide | New Drug Review | 3/17/2015 |
| 7400.13 | Office of New Drugs | Determining the Established Pharmacologic Class for Use in the Highlights of Prescribing Information | New Drug Review | 7/25/2018 |
| 4200.1 Rev.1 | Office of the Center Director | Procedures for Review of Protocols Referred By DEA That use Schedule I controlled Substances and Drugs | Leadership and Mission | 11/12/2020 |
| 4200.2 Rev. 1 | Office of the Center Director | Forecasting Schedule I and II Substance and Drug Needs | Leadership and Mission | 12/21/2020 |
| 4200.3 Rev.1 | Office of the Center Director | Consulting the Controlled Substance Staff on Abuse Liability, Drug Dependence, Risk Management, and Drug Scheduling | Drug Safety | 3/6/2017 |
| 4301.1Rev.3 | Office of Medical Policy | Center for Drug Evaluation and Research Medical Policy Council | Medical Policy | 2/23/2021 |
| 4655.3 Rev 4 | Office of Management | Procedures for CDER Medical Officer Conversion to Career-Conditional | Staff Resources and Services | 9/27/2018 |
| 4643.8 | Office of Management | Relocation Program | Staff Resources and Services | 1/18/2017 |
| 4642.1 | Office of Management | Policies and Procedures for Organizational Changes | Staff Resources and Services | 5/4/2007 |
| 4641.8 Rev.1 | Office of Management | Reimbursement for Professional Liability Insurance | Staff Resources and Services | 3/14/2014 |
| 4631.2 | Office of Management | Preparation of Purchase/Service/Stock Requisitions in iProcurement | Staff Resources and Services | 6/20/2013 |
| 4631.1 Rev.1 | Office of Management | Supplement to Authority to Make Allotments and Authorize the Establishment of Allowances | Staff Resources and Services | 6/20/2013 |
| 4601.3 Rev.2 | Office of Management | Children in the Workplace | Staff Resources and Services | 1/22/2021 |
| 4516.1 Rev 1 | Office of Communications | Criteria for Developing and Publishing Digital Content on the CDER External Web Site | Public Outreach | 3/12/2020 |
| 4512.2 Rev.2 | Office of Strategic Programs | Conducting Effective Meetings in CDER: Remote Access Considerations | Information Technology | 12/8/2021 |
| 4510.2 Rev.2 | Office of Regulatory Policy | CDER Clearance of FDA Related Articles,Speeches and Other Publications | Regulatory Policy and Information Disclosure | 9/17/2020 |
| 4510.1 Rev.1 | Office of Communications | CDER Authorization and Tracking of Outside Speaker Clearance | Public Outreach | 4/10/2013 |
| 4520.1 Rev. 2 | Office of Communications | Communicating Drug Approval Information | Public Outreach | 7/17/2017 |
| 5017.1Rev.1 | Office of Pharmaceutical Quality | Office of Biotechnology Products and Office of Pharmaceutical Manufacturing Assessment, Interactions on BLA Assessments | Regulatory Review and Scientific Policies | 5/01/2020 |
| 4658.3 Rev.3 | Office of Management | Requesting New Full -Time Equivalents | Staff Resources and Services | 12/8/2015 |
| 4657.9 Rev.5 | Office of Management | Restoration of Forfeited Annual Leave | Staff Resources and Services | 9/2/2021 |
| 5015.7 Rev.1 | Office of Pharmaceutical Quality | Environmental Assessments | Regulatory Review and Scientific Policies | 9/14/2017 |
| 5015.6 Rev.1 | Office of Pharmaceutical Quality | Review of Grouped Product Quality Supplements | Regulatory Review and Scientific Policies | 4/19/2016 |
| 5015.5 Rev.1 | Office of Pharmaceutical Quality | CMC Reviews of Type III DMF's for Packaging Materials | Regulatory Review and Scientific Policies | 10/18/2017 |
| 5015.8 | Office of Pharmaceutical Quality | Acceptance Criteria for Residual Solvents_MAPP | Regulatory Review and Scientific Policies | 6/28/2017 |
| 5016.1 | Office of Pharmaceutical Quality | Applying ICH Q8(R2), Q9, and Q10 Principles to CMC Review | Regulatory Review and Scientific Policies | 5/17/2016 |
| 5040.1 | Office of Pharmaceutical Quality | Product Quality Microbiology Information in the Common Technical Document - Quality (CTD-Q) | Regulatory Review and Scientific Policies | 1/25/2017 |
| 5100.3 | Office of Translational Sciences | OCP Prioritization, Triage, and Review Process for INDs and Pre-INDs | Regulatory Review and Innovation | 5/30/2006 |
| 5100.4 Rev.1 | Office of Translational Sciences | Scientific Interest Groups: Criteria and Policies. | Regulatory Review and Innovation | 9/1/2021 |
| 5100.5 | Office of Translational Sciences | An Integrated Genomics, Pharmacometrics, and Clinical Pharmacology Review Process | Regulatory Review and Innovation | 6/16/2010 |
| 5210.4 Rev 2 | Office of Generic Drugs | Review of Bioequivalence Studies with Clinical Endpoints in ANDAs | Generic Drug Review | 6/22/2017 |
| 5210.5 Rev.3 | Office of Generic Drugs | Review of Investigational New Drug Applications (Bio-INDs) by the Office of Generic Drugs | Generic Drug Review | 04/14/2022 |
| 5230.3 Rev.1 | Office of Generic Drugs | Generic Drug Labeling Revisions Covered Under Section 505(j)(10) of the Federal Food, Drug, and Cosmetic Act | Generic Drug Review | 7/27/2021 |
| 6020.4 Rev.2 | Office of New Drugs | Classifying Resubmissions of Original NDAs, BLAs, and Efficiacy Supplements in Response to Action Letters | New Drug Review | 2/26/2015 |
| 6020.2 Rev.1 | Office of New Drugs | Applications for Parenteral Products in Plastic Immediate Containers | New Drug Review | 4/9/2018 |
| 6010.9 | Office of New Drugs | Procedures and Responsibilities for Developing Postmarketing Requirements and Commitments | New Drug Review | 3/9/2009 |
| 6010.8 Rev.1 | Office of New Drugs | NDAs and BLAs: Communication to Applicants of Planned Review Timelines | New Drug Review | 8/25/2014 |
| 6010.6 | Office of New Drugs | The Use of Clinical Source Data in the Review of Marketing Applications | New Drug Review | 10/18/2010 |
| 6010.5 | Office of New Drugs | NDAs: Filing Review Issues | New Drug Review | 3/27/2018 |
| 6010.3 Rev.1 | Office of New Drugs | Good Review Practice: Clinical Review Template | New Drug Review | 12/10/2010 |
| 6010.2 | Office of New Drugs | Responsibilities for Tracking and Communicating the Status of Postmarketing Requirements and Commitments | New Drug Review | 7/28/2009 |
| 5210.9 Rev.1 | Office of Pharmaceutical Quality | Review of Botanical Drug Products | Regulatory Review and Scientific Policies | 11/8/2016 |
| 6004.2 Rev.2 | Office of New Drugs | Procedures for Completing and Processing the Form "Annual Status Report Review Form: PMR and PMC Summary" | New Drug Review | 9/27/2017 |
| 4190.1 Rev.3 | Office of the Center Director | Drug Shortage Management | Medical Policy | 11/30/2018 |
| 6002.4 | Office of New Drugs | Government-Issued Nonaccountable Personal Property | New Drug Review | 8/22/2016 |
| 6001.1 | Office of Executive Programs | Special Government Employees Representing Sponsors Before CDER | Executive Secretariat | 4/22/1996 |
| 5310.7 Rev.1 | Office of Pharmaceutical Quality | Acceptability of Standards From Alternative Compendia (BP/EP/JP) | Regulatory Review and Scientific Policies | 9/20/2017 |
| 5310.3 Rev.2 | Office of Pharmaceutical Quality | Requests for Expedited Review of New Drug Application and Biologics License Application Prior Approval Supplements Submitted for Chemistry, Manufacturing, and Controls Changes | Regulatory Review and Scientific Policies | 4/08/2021 |
| 6030.1 Rev.3 | Office of New Drugs | IND Process and Review Procedures (Including Clinical Holds) | New Drug Review | 2/20/2018 |
| 6025.3 | Office of New Drugs | Good Review Practice: Clinical Consultative Review of Drugs Regulated Within OND | New Drug Review | 5/16/2017 |
| 6025.1 | Office of New Drugs | Good Review Practices | New Drug Review | 2/27/2017 |
| 6020.14 | Office of New Drugs | Interdisciplinary Review Team for QT Studies | New Drug Review | 2/3/2012 |
| 6020.13 | Office of New Drugs | Good Review Practice: Clinical and Consultative Review of Drugs to Reduce the Risk of Cancer | New Drug Review | 5/16/2017 |
| 6020.8 Rev 1 | Office of New Drugs | Action Packages for NDAs and Efficacy Supplements | New Drug Review | 6/14/2016 |
| 6020.7 Rev.1 | Office of New Drugs | NDAs: Foreign Language Labeling | New Drug Review | 10/27/2014 |
| 6020.5 Rev. 2 | Office of New Drugs | Good Review Practice: OND Review Management of INDs and NDAs for Nonprescription Drug Products | New Drug Review | 6/25/2018 |
| 7700.2 | Office of Translational Sciences | Review and Conduct of Human Subject Research | Regulatory Review and Innovation | 5/18/2009 |
| 7610.2 Rev.1 | Office of Strategic Programs | Use of Government Electronic Equipment and Systems | Information Technology | 11/16/2012 |
| 7600.6 Rev.1 | Office of Strategic Programs | Requesting and Accepting Non-Archivable Records in Electronic Format for New Drug Applications | Information Technology | 9/3/2013 |
| 7500.2 Rev.1 | Office of New Drugs | Regulatory Project Management Site Tours and Regulatory Interactions Program | New Drug Review | 5/2/2017 |
| 7500.1 Rev. 2 | Office of New Drugs | Regulatory Project Management Coordinating Committee | New Drug Review | 9/5/2018 |
| 7400.4 Rev.1 | Office of New Drugs | Tertiary Review of Genetic Toxicology Studies Resulting in a Recommendation for a Clinical Hold or Conduct of Additional Studies | New Drug Review | 2/25/2015 |
| 7400.1 Rev.2 | Office of New Drugs | Management of CDER Pharmacology/Toxicology Coordinating Committee and Its Associated Subcommittees and Working Groups | New Drug Review | 5/17/2016 |
| 6720.2 Rev.1 | Office of Surveillance and Epidemiology | Procedures for Handling Requests for Proprietary Name Review | Drug Safety | 1/8/2016 |
| 6700.5 | Office of Surveillance and Epidemiology | Responding to Requests For Waivers of Postmarketing Safety Reporting Requirements under 21 CFR §§ 314.80 (NDAs), 314.98 (ANDAs), and 600.80 (BLAs) | Drug Safety | 3/1/2012 |
| 6700.9 | Office of Surveillance and Epidemiology | 6700.9 (PDF - 121KB) FDA Posting of Potential Signals of Serious Risks Identified by the Adverse Event Reporting System | Drug Safety | 9/10/2019 |
| 6610.1 Rev. 2 | Office of Translational Sciences and Biostatistics | Statistical Policy Council | Regulatory Review and Innovation | 6/1/2021 |
| 6050.1 Rev. 2 | Office of Management | Effect of Failure to Pay PDUFA Fees | Staff Resources and Services | 12/03/2021 |
| 6030.9 | Office of New Drugs | Good Review Practice: Good Review Management Principles and Practices for Effective IND Development and Review | New Drug Review | 4/29/2013 |
| 6030.8 Rev.1 | Office of New Drugs | INDs: Exception from Informed Consent Requirements for Emergency Research | New Drug Review | 11/17/2014 |
| 6030.6 | Office of New Drugs | INDs: Processing Treatment INDs and Treatment Protocols | New Drug Review | 12/9/2011 |
| 6030.2 Rev.1 | Office of New Drugs | INDs: Review of Informed Consent Documents | New Drug Review | 5/2/2014 |
| 6020.3 Rev.2 | Office of New Drugs | Review Designation Policy: Priority (P) and Standard (S) | New Drug Review | 6/25/2013 |
| 5240.5 Rev.2 | Office of Generic Drugs | ANDA Suitability Petitions | Generic Drug Review | 10/9/2020 |
| 7610.5 | Office of Strategic Programs | Government Issued Computers For CDER Employees | Information Technology | 4/9/2014 |
| 7620.6 | Office of the Center Director | Preparation of Topics and Nomination of Experts For Development and Harmonization of International Scientific and Technical Guidelines | Information Technology | 9/25/2013 |
| 7610.6 | Office of Strategic Programs | CDER Electronic Application Forms Oversight | Information Technology | 10/3/2013 |
| 6025.4 | Office of New Drugs | Good Review Practice: Refuse to File | New Drug Review | 9/5/2018 |
| 4657.4 | Office of Management | Intra-Center Detail Program | Staff Resources and Services | 11/25/2013 |
| 6025.2 | Office of New Drugs | Good Review Practice: Clinical Review of Investigational New Drug Applications | New Drug Review | 3/5/2018 |
| 4643.9 Rev.1 | Office of Management | Change in Duty Station | Staff Resources & Services | 5/6/2019 |
| 7412.1 Rev.2 | Office of New Drugs | Management of CDER Executive Carcinogenicity Assessment Committee and Communication of Committee Proceedings | New Drug Review | 6/8/2018 |
| 7412.2 Rev.1 | Office of New Drugs | Management of CDER Carcinogenicity Assessment Committee and Communication of Committee Proceedings | New Drug Review | 6/7/2018 |
| 4642.3 | Office of Management | Student Volunteer Employment Program (SVEP) | Staff Resources and Services | 9/28/2018 |
| 4643.4 | Office of Management | CDER OFFICE SPACE REQUESTS | Staff Resources and Services | 6/18/2014 |
| 4657.12 Rev.1 | Office of Management | Voluntary Leave Transfer Program | Staff Resources and Services | 6/24/2014 |
| 4643.5 | Office of Management | CONFERENCE ROOM MANAGEMENT | Staff Resources and Services | 7/17/2014 |
| 6025.6 | Office of New Drugs | Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics | New Drug Review | 7/29/2014 |
| 4130.1 | Office of the Center Director | Drug Development Tool Qualification Programs | Leadership and Mission | 7/30/2014 |
| 5016.3 | Office of Pharmaceutical Quality | Responsibility in OPQ for the Integrated Quality Assessment of Products Containing Drug Substances Composed of Amino Acid Polymers | Regulatory Review and Scientific Policies | 12/11/2018 |
| 5016.4 | Office of Pharmaceutical Quality | Clarification Teleconferences Between Sponsors, Applicants, or Master File Holders And the ONDQA Review Team | Regulatory Review and Scientific Policies | 8/1/2014 |
| 4643.2 | Office of Management | CDER Copier Management Program | Staff Resources and Services | 9/18/2014 |
| 7600.11 | Office of Strategic Programs | CDER Electronic Record Keeping System | Information Technology | 9/29/2014 |
| 4100.1 Rev.2 | Office of Management | CDER Co-Sponsorship Agreements for Events | Staff Resources and Services | 6/21/2021 |
| 4643.1 | Office of Management | WORKPLACE ERGONOMIC EVALUATION REQUESTS | Staff Resources and Services | 10/22/2014 |
| 7700.5 Rev.1 | Office of Translational Sciences | Critical Path Innovation Meetings Policy and Procedures | Regulatory Review and Innovation | 04/14/2021 |
| 5015.1 | Office of Pharmaceutical Quality | Chemistry Review of Question-based Review (QbR) Submissions | Regulatory Review and Scientific Policies | 11/19/2014 |
| 4001.1 | Office of Managment | Developing, Issuing and Maintaining Standard Operating Procedures for CDER | Staff Resources and Services | 1/12/2015 |
| 4657.5 Rev.3 | Office of Management | Advanced Annual and Sick Leave | Staff Resources and Services | 2/25/2015 |
| 6025.7 | Office of New Drugs | Good Review Practice: Review of Marketing Applications for Breakthrough Therapy-Designated Drugs and Biologics That Are Receiving an Expedited Review | New Drug Review | 3/9/2015 |
| 4651.4 Rev.1 | Office of Management | CDER Incentive Awards Program (Cash and Time-off) | Staff Resources and Services | 7/16/2020 |
| 4631.4 | Office of Management | Monitoring and De-obligating Undelivered Orders (UDOs) | Staff Resources and Services | 6/16/2015 |
| 4800.2 Rev.1 | Office of the Center Director | Continuity of Operations (COOP) | Leadership and Mission | 7/21/2021 |
| 7610.7 Rev.1 | Office of Strategic Programs | CDER Data Standards Program | Information Technology | 8/31/2021 |
| 4657.11Rev.1 | Office of Management | Religious Compensatory Time | Staff Resources and Services | 10/13/2015 |
| 5241.2 Rev. 1 | Office of Generic Drugs | Consolidation of ANDAs by the Office of Generic Drugs | Generic Drug Review | 8/19/2020 |
| 6001.2 Rev.1 | Office of the Center Director | CDER Network Of Experts | Leadership and Mission | 10/12/2021 |
| 5018.2 | Office of Pharmaceutical Quality | NDA Classification Codes | Regulatory Review and Scientific Policies | 11/3/2015 |